![]() |
JOURNAL TOOLS |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Publication history |
Estratti |
Permessi |
Per citare questo articolo |

I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW
Minerva Medica 2020 December;111(6):589-600
DOI: 10.23736/S0026-4806.20.06821-4
Copyright © 2020 EDIZIONI MINERVA MEDICA
lingua: Inglese
Challenges and new perspectives in the treatment of advanced cutaneous squamous cell carcinoma
Gabriella BRANCACCIO 1, Elvira MOSCARELLA 1, Giulia BRIATICO 1, Pasquale VEROLINO 2, Roberto ALFANO 3, Giuseppe ARGENZIANO 1 ✉
1 Dermatology Unit, Luigi Vanvitelli University of Campania, Naples, Italy; 2 Plastic Surgery Unit, Multidisciplinary Department of Medical-Surgical and Dental Specialties, Luigi Vanvitelli University of Campania, Naples, Italy; 3 Department of Anesthesiology, Surgery and Emergency, Luigi Vanvitelli University of Campania, Naples, Italy
Despite the overall excellent survival rates in patients affected by early cutaneous squamous cell carcinoma (CSCC), advanced forms of CSCC are associated with high patient mortality. To date, only limited therapeutic modalities have been implemented, including chemotherapy and radiotherapy. Systemic therapy was enriched by the addition of epidermal growth factor receptor inhibitors (EGFRi) in the last years. Unfortunately, the overall outcome of all these therapeutic strategies remains poor, therefore important unmet clinical needs persist. Thanks to a better understanding of the biology of advanced CSCC, new treatment options are now available. This article presents the current definition of advanced CSCC along with actual therapeutic options and discusses the strengths and limitations of a new promising systemic approach, which involves the use of immune checkpoint inhibitors.
KEY WORDS: Squamous cell carcinoma; Skin neoplasms; Drug therapy; Radiotherapy; ErbB receptors